We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Will Skyrizi & Rinvoq Drive AbbVie's Top-Line Growth in Q3?
Read MoreHide Full Article
Key Takeaways
AbbVie's Skyrizi and Rinvoq are expected to sustain growth despite Humira's ongoing sales erosion.
Skyrizi sales are estimated at $5.71 billion, up 21%, while Rinvoq is expected to rise 25% to $2.73 billion.
J&J's Tremfya and Icotyde, along with Lilly's Omvoh, intensify competition in immunology.
AbbVie (ABBV - Free Report) is scheduled to report its third-quarter 2026 results on Oct. 30, before the opening bell. Investors will likely focus on the sales growth of its immunology franchise, which is led by two blockbuster medications, Skyrizi and Rinvoq.
Strong demand for both drugs has helped AbbVie sustain top-line growth despite the U.S. loss of exclusivity for its legacy drug Humira in 2023. Skyrizi and Rinvoq collectively overlap with Humira across several major inflammatory conditions, plus a distinct new indication, atopic dermatitis. Both products have delivered strong growth across approved indications, particularly in the inflammatory bowel disease (IBD) market, which includes ulcerative colitis (UC) and Crohn’s disease (CD).
Continued growth in the immunology market, market-share gains and uptake across newer indications are expected to support sales. In July 2026, the European Commission approved Rinvoq for vitiligo and severe alopecia areata, expanding its potential growth opportunities. Applications for both indications are under review in the United States.
The Zacks Consensus Estimate for Skyrizi sales is pegged at $5.71 billion, while the same for Rinvoq stands at $2.73 billion. These figures imply year-over-year growth of approximately 21% and 25%, respectively, based on third-quarter 2025 sales. Continued demand across approved indications and further market-share gains are expected to support their performance.
Sales of both drugs are also expected to offset the decline in Humira, which is expected to continue its downward trajectory due to generic erosion. The Zacks Consensus Estimate for the drug’s sales is pegged at $688 million, indicating a decline of about 31% year over year.
Beyond immunology, AbbVie has expanded its presence in neuroscience and oncology. Over the past few years, the company’s neuroscience franchise spans migraine and Parkinson’s disease treatments, while its oncology portfolio has expanded beyond blood cancers into solid tumors. Nevertheless, the performance of Skyrizi and Rinvoq will remain central to assessing whether growth in AbbVie’s newer immunology drugs can continue to offset Humira’s erosion.
ABBV’s Competition in the Immunology Space
The immunology market is highly competitive, with major pharmaceutical companies vying for market share across several indications. A key competitor is Johnson & Johnson (JNJ - Free Report) , which markets two major immunology drugs, Stelara and Tremfya. Both drugs are approved for multiple inflammatory conditions, including UC and CD. Following the entry of Stelara biosimilars in the United States in 2025, J&J is increasingly relying on Tremfya’s growth to offset declining Stelara sales and support its immunology franchise.
Eli Lilly (LLY - Free Report) is another competitor expanding its presence in immunology through Omvoh. The drug received FDA approval for UC in October 2023 and for CD in January 2025. These approvals established the LLY drug as a competitor in both the major forms of IBD, where AbbVie’s Skyrizi has been gaining traction.
ABBV’s Price Performance, Valuation and Estimates
This year so far, shares of AbbVie have risen 21% compared with the industry’s 12.5% growth.
Image Source: Zacks Investment Research
From a valuation standpoint, AbbVie is trading at a slight discount to the industry. Based on the price/earnings (P/E) ratio, the company’s shares currently trade at 17.75 times forward earnings, lower than its industry’s average of 18.18 times.
Image Source: Zacks Investment Research
The bottom-line estimate per share for 2026 has declined from $14.05 to $13.98, while the 2027 estimate has fallen from $16.15 to $16.04 over the past 30 days.
View the Zacks #1 Rank List
Image: Shutterstock
Will Skyrizi & Rinvoq Drive AbbVie's Top-Line Growth in Q3?
Key Takeaways
AbbVie (ABBV - Free Report) is scheduled to report its third-quarter 2026 results on Oct. 30, before the opening bell. Investors will likely focus on the sales growth of its immunology franchise, which is led by two blockbuster medications, Skyrizi and Rinvoq.
Strong demand for both drugs has helped AbbVie sustain top-line growth despite the U.S. loss of exclusivity for its legacy drug Humira in 2023. Skyrizi and Rinvoq collectively overlap with Humira across several major inflammatory conditions, plus a distinct new indication, atopic dermatitis. Both products have delivered strong growth across approved indications, particularly in the inflammatory bowel disease (IBD) market, which includes ulcerative colitis (UC) and Crohn’s disease (CD).
Continued growth in the immunology market, market-share gains and uptake across newer indications are expected to support sales. In July 2026, the European Commission approved Rinvoq for vitiligo and severe alopecia areata, expanding its potential growth opportunities. Applications for both indications are under review in the United States.
The Zacks Consensus Estimate for Skyrizi sales is pegged at $5.71 billion, while the same for Rinvoq stands at $2.73 billion. These figures imply year-over-year growth of approximately 21% and 25%, respectively, based on third-quarter 2025 sales. Continued demand across approved indications and further market-share gains are expected to support their performance.
Sales of both drugs are also expected to offset the decline in Humira, which is expected to continue its downward trajectory due to generic erosion. The Zacks Consensus Estimate for the drug’s sales is pegged at $688 million, indicating a decline of about 31% year over year.
Beyond immunology, AbbVie has expanded its presence in neuroscience and oncology. Over the past few years, the company’s neuroscience franchise spans migraine and Parkinson’s disease treatments, while its oncology portfolio has expanded beyond blood cancers into solid tumors. Nevertheless, the performance of Skyrizi and Rinvoq will remain central to assessing whether growth in AbbVie’s newer immunology drugs can continue to offset Humira’s erosion.
ABBV’s Competition in the Immunology Space
The immunology market is highly competitive, with major pharmaceutical companies vying for market share across several indications. A key competitor is Johnson & Johnson (JNJ - Free Report) , which markets two major immunology drugs, Stelara and Tremfya. Both drugs are approved for multiple inflammatory conditions, including UC and CD. Following the entry of Stelara biosimilars in the United States in 2025, J&J is increasingly relying on Tremfya’s growth to offset declining Stelara sales and support its immunology franchise.
J&J is also expanding its immunology portfolio. Earlier in March, it secured approval for Icotyde, a once-daily oral drug for moderate-to-severe plaque psoriasis. While still in the early stages of launch, the drug could pose a competitive threat to Skyrizi.
Eli Lilly (LLY - Free Report) is another competitor expanding its presence in immunology through Omvoh. The drug received FDA approval for UC in October 2023 and for CD in January 2025. These approvals established the LLY drug as a competitor in both the major forms of IBD, where AbbVie’s Skyrizi has been gaining traction.
ABBV’s Price Performance, Valuation and Estimates
This year so far, shares of AbbVie have risen 21% compared with the industry’s 12.5% growth.
Image Source: Zacks Investment Research
From a valuation standpoint, AbbVie is trading at a slight discount to the industry. Based on the price/earnings (P/E) ratio, the company’s shares currently trade at 17.75 times forward earnings, lower than its industry’s average of 18.18 times.
Image Source: Zacks Investment Research
The bottom-line estimate per share for 2026 has declined from $14.05 to $13.98, while the 2027 estimate has fallen from $16.15 to $16.04 over the past 30 days.
Image Source: Zacks Investment Research
AbbVie currently carries a Zacks Rank #4 (Sell).
You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.